Jump to navigation Jump to search
Eperison Wiki Str.png
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
ATC code
Legal status
Legal status
  • not licensed
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass259.387 g/mol
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Eperisone


Most recent articles on Eperisone

Most cited articles on Eperisone

Review articles on Eperisone

Articles on Eperisone in N Eng J Med, Lancet, BMJ


Powerpoint slides on Eperisone

Images of Eperisone

Photos of Eperisone

Podcasts & MP3s on Eperisone

Videos on Eperisone

Evidence Based Medicine

Cochrane Collaboration on Eperisone

Bandolier on Eperisone

TRIP on Eperisone

Clinical Trials

Ongoing Trials on Eperisone at Clinical Trials.gov

Trial results on Eperisone

Clinical Trials on Eperisone at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Eperisone

NICE Guidance on Eperisone


FDA on Eperisone

CDC on Eperisone


Books on Eperisone


Eperisone in the news

Be alerted to news on Eperisone

News trends on Eperisone


Blogs on Eperisone


Definitions of Eperisone

Patient Resources / Community

Patient resources on Eperisone

Discussion groups on Eperisone

Patient Handouts on Eperisone

Directions to Hospitals Treating Eperisone

Risk calculators and risk factors for Eperisone

Healthcare Provider Resources

Symptoms of Eperisone

Causes & Risk Factors for Eperisone

Diagnostic studies for Eperisone

Treatment of Eperisone

Continuing Medical Education (CME)

CME Programs on Eperisone


Eperisone en Espanol

Eperisone en Francais


Eperisone in the Marketplace

Patents on Eperisone

Experimental / Informatics

List of terms related to Eperisone

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Eperisone (formulated as the eperisone hydrochloride salt) is an antispasmodic drug.

Eperisone acts by relaxing both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. The drug inhibits the vicious circle of myotonia by decreasing pain, ischaemia, and hypertonia in skeletal muscles, thus alleviating stiffness and spasticity, and facilitating muscle movement[1]

Eperisone also improves dizziness and tinnitus associated with cerebrovascular disorders or cervical spondylosis.

Eperisone has a relatively low incidence of sedation when compared with other antispasmodic drugs; this simplifies the clinical application of the drug and makes it an attractive choice for patients who require antispasmodic therapy without a reduction in alertness.

Eperison Jpn.png

Eperisone also facilitates voluntary movement of the upper and lower extremities without reducing muscle power; it is therefore useful during the initial stage of rehabilitation and as a supporting drug during subsequent rehabilitative therapy.



Eperisone hydrochloride is available as the brand name preparation Myonal as 50 mg sugar coated tablets, or as 10% granules for oral administration.[6] An experimental form of the drug, as a transdermal patch system, has shown promising results in laboratory tests on rodents; however, this product is not currently available for human use.[7] It is also available as the brand name Epry as 50 mg as sugar coated tablets.

Dosage and administration

In adults, the usual dose of eperisone is 50–150 mg per day, in divided doses, after meals. However, the dosage is adjusted by the prescribing clinician depending on factors such as severity of symptoms, patient age and response.

Eperisone has not been established as definitely safe for paediatric use, therefore its use in paediatrics cannot be recommended without further study.[6]

If elderly patients are treated with eperisone, a reduced dose is recommended, and the patient should be closely monitored for signs of psychological hypofunction during treatment.[6]

Safety during pregnancy and breast-feeding

Eperisone has not been established to be safe for use by pregnant women; therefore the drug should only be used in pregnant women, or women who may be pregnant, if the expected therapeutic benefits will outweigh the possible risks associated with treatment. The manufacturers of Myonal recommend the drug not be used during lactation (breast-feeding). If eperisone must be used, the patient is advised to stop breast-feeding for the duration of treatment. Eperisone has beed reported to be excreted in breast milk in an animal study (in rats).



Eperisone is contraindicated in patients with known hypersensitivity to the drug.[8] Side effects: 'very rare' excessive relaxation, stomachache, nausea, vertigo, anorexia, drowsiness, skin rashes, diarrhoea, vomiting, indigestion, GI disturbances, insomnia, headache, constipation etc.[9]


Eperisone should be administered with care in patients with a history of hypersensitivity to any medication, or with disorders of liver function (it may aggravate hepatic dysfunction).

Weakness, light-headedness, sleepiness or other symptoms may occur. In the event of such symptoms, the dosage should be reduced or treatment discontinued. Patients should be cautioned against engaging in potentially hazardous activities requiring alertness, such as operating machinery or driving a car.[6]

Side effects

Drug interactions

There have been reports of disturbances in ocular accommodation occurring after the concomitant use of the related drug tolperisone hydrochloride and methocarbamol.

Safety in overdose

Seizures have been reported in an infant after accidental ingestion of eperisone.[11]

Future developments

Eperisone suffers from a very low bioavailability when taken orally, as a result of high first pass intestinal metabolism; a transdermal patch containing eperisone is currently in development in South Korea.[1] This has shown promise, with the antispasmodic effect lasting over 24 hours, compared to one to two hours following oral administration.

Eperisone is also under investigation as an antihypertensive agent, with promising results from trials on beagles.[12]

Brand names

Eperisone is sold in Bangladesh, China, India, Indonesia, Japan, United Arab Emirates, Malaysia, the Philippines, Thailand, Sudan and Pakistan under the brand name Myonal[13] and in Italy under the brand name Expose.[14]

See also


  1. 1.0 1.1 Yang SI, Park HY, Lee SH; et al. (July 2004). "Transdermal eperisone elicits more potent and longer-lasting muscle relaxation than oral eperisone". Pharmacology. 71 (3): 150–6. doi:10.1159/000077449. PMID 15161997.
  2. http://www.curehunter.com/public/keywordSummaryC030848--4--ethyl-2-methyl-3-piperidino-propiophenone.do
  3. Bose K (1999). "The efficacy and safety of eperisone in patients with cervical spondylosis: Results of a randomized, double-blind, placebo-controlled trial". Methods Find Exp Clin Pharmacol. 21 (3): 209–13. doi:10.1358/mf.1999.21.3.534831. PMID 10389124.
  4. 4.0 4.1 http://squarepharma.com.bd/SPL_PI_PDF/myonil226.pdf
  5. http://www.europeanreview.org/articolo.php?id=502
  6. 6.0 6.1 6.2 6.3 http://di.eisai.co.jp/di/EPI/MYO_T-G_EPI.pdf
  7. Yang Sang-In (July 2004). "Transdermal eperisone elicits more potent and longer-lasting muscle relaxation than oral eperisone". Pharmacology. 71 (3): 150–6. doi:10.1159/000077449. PMID 15161997. Unknown parameter |coauthors= ignored (help)
  8. Clinical trial number NCT00327730 for "Evaluation of Eperisone HCl in the Treatment of Acute Musculoskeletal Spasm Associated With Low Back Pain" at ClinicalTrials.gov
  9. http://www.squarepharma.com.bd/SPL_PI_PDF/myonil226.pdf
  10. Ueno T, Kawana S (July 2007). "[A case of eperisone hydrochloride (myonal)--induced drug eruption leading to erythema and angioedema]". Arerugi (in Japanese). 56 (7): 709–13. PMID 17671415.
  11. Tanno K, Narimatsu E, Takeyama Y, Asai Y (May 2007). "Infantile case of seizure induced by intoxication after accidental consumption of eperisone hydrochloride, an antispastic agent". Am J Emerg Med. 25 (4): 481–2. doi:10.1016/j.ajem.2006.09.002. PMID 17499672.
  12. Template:Patent
  13. http://goliath.ecnext.com/coms2/gi_0199-451231/Tokyo-pharma-stocks-week-to.html
  14. http://www.torrinomedica.it/farmaci/schedetecniche/Expose.asp